William W. Crouse
Founder at Encore Dermatology, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gilles Alberici | M | 67 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | - |
Zoe Evans | F | - |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | - |
Ian Lobley | M | 61 |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | - |
Bryan Geoffrey Morton | M | 67 |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 19 years |
Göran Albert Ando | M | 75 |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | - |
Dan R. Burns | M | 72 |
InfaCare Pharmaceutical Corp.
InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | 17 years |
Robert A. Vukovich | M | - |
InfaCare Pharmaceutical Corp.
InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | 23 years |
Michael Brown | M | - |
Encore Dermatology, Inc.
Encore Dermatology, Inc. Medical SpecialtiesHealth Technology Encore Dermatology, Inc. manufactures prescription therapies and medical devices for dermatologists. It offers hylatopicplus emollient foam, hylatopicplus cream, and tetrix cream to manage and relieve the burning, itching, and pain. The company was founded Robert J. Moccia and Michael Brown in 2015 and is headquartered in Malvern, PA. | - |
Pablo D. T. Valenzuela | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
F. Carsten Thiel | M | 61 |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | 3 years |
Carol Strange | F | - |
Lehigh University
| - |
William J. Rutter | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | 31 years |
Carina Sitkus | F | - |
Lehigh University
| - |
Thomas N. Urban | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Meg Stone | F | - |
Lehigh University
| - |
Patricia Johnson | F | 68 |
Lehigh University
| 10 years |
Evis Hursever | M | - |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | - |
Richard Verma | M | 55 |
Lehigh University
| - |
Steve C. Pettit | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Patrick Smith | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Deshui Zhang | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Brodi Jackson | F | - |
Lehigh University
| 8 years |
Emil Stanislaw Slazak | M | - |
Lehigh University
| - |
Chris Samuel-Maynard | M | - |
Lehigh University
| - |
Tara Stacom | F | 66 |
Lehigh University
| 21 years |
Paul Davisson | M | - |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | - |
Susan Vengrove | F | - |
Lehigh University
| - |
Emily Groff | F | - |
Lehigh University
| - |
David Ruvenstein | M | - |
Lehigh University
| - |
Chloe Abshire | F | - |
Lehigh University
| - |
Ingrid Green | F | - |
Lehigh University
| - |
Andrew Dorriere | M | - |
Lehigh University
| - |
Brian Jackson | M | - |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | 15 years |
Olivia Miller | F | - |
Lehigh University
| - |
Nicole Burke | F | - |
Lehigh University
| - |
Naomi Coll | F | - |
Lehigh University
| - |
Katie Uhrich | F | - |
Lehigh University
| - |
Carol Bene | F | - |
Lehigh University
| - |
Angelina RodrÃguez | F | - |
Lehigh University
| - |
Richard Hayne | M | 76 |
Lehigh University
| - |
E. Ronald Goldfuss | M | - |
InfaCare Pharmaceutical Corp.
InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | 19 years |
William H. Rutter | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Mark Van Mactas | M | 71 |
Lehigh University
| 13 years |
Hal R. Werner | M | 75 |
InfaCare Pharmaceutical Corp.
InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | 16 years |
Eugene D. Mercy | M | - |
Lehigh University
| - |
Margaret B. Glick | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | 11 years |
William F. Hecht | M | 81 |
Lehigh University
| - |
Dennis Singleton | M | 79 |
Lehigh University
| - |
Elliot Sussman | M | 72 |
Lehigh University
| - |
Patrick Enright | M | 62 |
InfaCare Pharmaceutical Corp.
InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | 18 years |
Frank E. Walsh | M | 58 |
Lehigh University
| - |
Stuart Ryan | M | 65 |
Lehigh University
| - |
Michael D. Zisman | M | 75 |
Lehigh University
| - |
Adele Oliva | F | 58 |
Encore Dermatology, Inc.
Encore Dermatology, Inc. Medical SpecialtiesHealth Technology Encore Dermatology, Inc. manufactures prescription therapies and medical devices for dermatologists. It offers hylatopicplus emollient foam, hylatopicplus cream, and tetrix cream to manage and relieve the burning, itching, and pain. The company was founded Robert J. Moccia and Michael Brown in 2015 and is headquartered in Malvern, PA. | - |
Petri T. Vainio | M | 65 |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | - |
Randy J. Semadeni | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Peter Gilbert | M | - |
Lehigh University
| - |
Charles W. Stiefel | M | - |
Encore Dermatology, Inc.
Encore Dermatology, Inc. Medical SpecialtiesHealth Technology Encore Dermatology, Inc. manufactures prescription therapies and medical devices for dermatologists. It offers hylatopicplus emollient foam, hylatopicplus cream, and tetrix cream to manage and relieve the burning, itching, and pain. The company was founded Robert J. Moccia and Michael Brown in 2015 and is headquartered in Malvern, PA. | - |
Volker Huelck | M | 84 |
Lehigh University
| - |
Kevin Clayton | M | 62 |
Lehigh University
| - |
Simon Peter Ball | M | 64 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | - |
Cynthia R. Cook | F | 55 |
Lehigh University
| - |
R. Barry | M | 52 |
Encore Dermatology, Inc.
Encore Dermatology, Inc. Medical SpecialtiesHealth Technology Encore Dermatology, Inc. manufactures prescription therapies and medical devices for dermatologists. It offers hylatopicplus emollient foam, hylatopicplus cream, and tetrix cream to manage and relieve the burning, itching, and pain. The company was founded Robert J. Moccia and Michael Brown in 2015 and is headquartered in Malvern, PA. | - |
Dmitri Vezenov | M | - |
Lehigh University
| - |
Seymour H. Fein | M | 75 |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | 9 years |
Ann Lewnes | F | 62 |
Lehigh University
| 3 years |
Ning Huang | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Greg A. Unruh | M | - |
Ventria Bioscience, Inc.
Ventria Bioscience, Inc. BiotechnologyHealth Technology Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO. | - |
Gina McCormick | F | - |
Lehigh University
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Terrance K. Wallberg | M | 69 |
Oxford Ventures, Inc.
| - |
Kerry P. Gray | M | 71 |
Oxford Ventures, Inc.
| 10 years |
Harlan Waksal | M | 71 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 21 years |
Glenn Sblendorio | M | 68 | 16 years | |
Eric Aguiar | M | 62 |
HealthCare Ventures LLC
HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | 5 years |
Jeffrey Davis | M | 61 |
Oxford Ventures, Inc.
| 9 years |
David Stack | M | 72 | 3 years | |
George Eldridge | M | 61 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 3 years |
Albert B. Plant | M | - |
Oxford Ventures, Inc.
| - |
Robert G. Savage | M | 70 | 13 years | |
Philip Frost | M | 84 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 years |
Neera D. Ravindran | M | - | - | |
John V. St. John | M | 53 | 6 years | |
Hiroaki Shigeta | M | 81 | - | |
Steven Hubrig Koehler | M | 73 | 4 years | |
Melvin Spigelman | M | 75 | 13 years | |
Fred M. Ryan | M | 72 | 5 years | |
Tony Vernon | M | 69 | 3 years | |
Elizabeth Hamilton Seabury Wyatt | M | 76 | - | |
Eric Rowinsky | M | 67 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 4 years |
Dennis P. Reilly | M | 65 | 3 years | |
Daniel Lynch | M | 65 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 4 years |
John Kelley | M | 70 | 5 years | |
Alexander Denner | M | 54 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 5 years |
Paul Antinori | M | 70 | 12 years | |
Mark Leschly | M | 55 |
HealthCare Ventures LLC
HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | 5 years |
Robert Hugin | M | 69 | 15 years | |
Sarah Schlesinger | M | 64 | 2 years | |
Bill O'Connor | M | 64 | 12 years | |
Tony Kingsley | M | 60 | 1 years | |
Gregory C. Williams | M | 65 | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 95 | 95.00% |
United Kingdom | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William W. Crouse
- Personal Network